PET imaging in patients with meningioma-report of the RANO/PET Group

TY - JOUR

T1 - PET imaging in patients with meningioma-report of the RANO/PET Group

AU - Galldiks, Norbert

AU - Albert, Nathalie L

AU - Sommerauer, Michael

AU - Grosu, Anca L

AU - Ganswindt, Ute

AU - Law, Ian

AU - Preusser, Matthias

AU - Le Rhun, Emilie

AU - Vogelbaum, Michael A

AU - Zadeh, Gelareh

AU - Dhermain, Frédéric

AU - Weller, Michael

AU - Langen, Karl-Josef

AU - Tonn, Jörg C

N1 - © The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected].

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Meningiomas are the most frequent nonglial primary brain tumors and represent about 30% of brain tumors. Usually, diagnosis and treatment planning are based on neuroimaging using mainly MRI or, rarely, CT. Most common treatment options are neurosurgical resection and radiotherapy (eg, radiosurgery, external fractionated radiotherapy). For follow-up after treatment, a structural imaging technique such as MRI or CT is used. However, these structural imaging modalities have limitations, particularly in terms of tumor delineation as well as diagnosis of posttherapeutic reactive changes. Molecular imaging techniques such as PET can characterize specific metabolic and cellular features which may provide clinically relevant information beyond that obtained from structural MR or CT imaging alone. Currently, the use of PET in meningioma patients is steadily increasing. In the present article, we provide recommendations for the use of PET imaging in the clinical management of meningiomas based on evidence generated from studies being validated by histology or clinical course.

AB - Meningiomas are the most frequent nonglial primary brain tumors and represent about 30% of brain tumors. Usually, diagnosis and treatment planning are based on neuroimaging using mainly MRI or, rarely, CT. Most common treatment options are neurosurgical resection and radiotherapy (eg, radiosurgery, external fractionated radiotherapy). For follow-up after treatment, a structural imaging technique such as MRI or CT is used. However, these structural imaging modalities have limitations, particularly in terms of tumor delineation as well as diagnosis of posttherapeutic reactive changes. Molecular imaging techniques such as PET can characterize specific metabolic and cellular features which may provide clinically relevant information beyond that obtained from structural MR or CT imaging alone. Currently, the use of PET in meningioma patients is steadily increasing. In the present article, we provide recommendations for the use of PET imaging in the clinical management of meningiomas based on evidence generated from studies being validated by histology or clinical course.

U2 - 10.1093/neuonc/nox112

DO - 10.1093/neuonc/nox112

M3 - Review

C2 - 28605532

SN - 1522-8517

VL - 19

SP - 1576

EP - 1587

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 12

ER -